MannKind Corporation (MNKD)

Over the past six months, MannKind's stock price has experienced a decline. In Q3 2025, MannKind reported earnings per share of $0.03, surpassing estimates, with revenue increasing by 17.1% year-over-year. The acquisition of scPharmaceuticals, strengthening its portfolio with FUROSCIX, was viewed positively. The FDA approved an updated Afrezza label providing starting dose guidance. Business updates outlining growth drivers for 2026 led to a stock gain. A supplemental BLA for Afrezza was accepted for review, aiming to expand the label to include pediatric patients.

Based on the available information, there is no explicit mention or indication of demand seasonality for MannKind Corp.'s products and services.

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing inhaled therapeutic products for chronic diseases, operating within the Healthcare sector and Biotechnology industry. The company is dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. Its major products include Afrezza, an ultra-rapid-acting inhaled insulin; V-Go, a wearable insulin delivery device; and Tyvaso DPI, for the treatment of pulmonary arterial hypertension. MannKind's product pipeline also includes MNKD-101, MNKD-201, MNKD-301, Pediatric Afrezza, and FUROSCIX.

MannKind Corporation primarily focuses its development and commercialization efforts in the United States. The company's official headquarters moved to Danbury, Connecticut, in 2022, where its Afrezza manufacturing facility is also located. It also maintains a corporate office in Westlake Village, California. Beyond the U.S., MannKind has supply and distribution agreements for Afrezza in Brazil with Biomm S.A. and in India with Cipla Ltd.

MannKind's brand reputation in the past year appears to be generally positive, driven by product development and financial performance. The company reported record revenue in Q3 2025 and consistent revenue growth, particularly from its Tyvaso DPI collaboration. The acquisition of scPharmaceuticals and its product FUROSCIX was seen as a positive strategic move. The FDA approval of an updated Afrezza label and the acceptance of a supplemental BLA for pediatric use are positive developments.

The ownership structure of MannKind stock includes institutional, retail, and individual investors. Approximately 27.89% of the company's stock is owned by Institutional Investors, 2.92% by Insiders, and 69.20% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Rubric Capital Management LP, State Street Corp., Geode Capital Management, Llc, Nitorum Capital, L.P., and UBS Group AG.